From genes to characteristics of multiple sclerosis

Acta Neurologica Scandinavica

Volumn 126, Issue S195, 2012, Pages 76-83

  Harbo, H F ^a,b   Mero, I L ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Genes; Genome wide association studies; HLA; Multiple sclerosis

Indexed keywords

HLA B44 ANTIGEN; HLA DRB1 ANTIGEN; VITAMIN D;

ARTICLE; BEHAVIOR; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HERITABILITY; HLA SYSTEM; HUMAN; IMMUNITY; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; PHENOTYPE; POPULATION GENETICS; SMOKING; TREATMENT OUTCOME; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE FACILITY; IMMUNOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

BIOLOGICAL SPECIMEN BANKS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883474389     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12027     Document Type: Article

References (63)

1. Smestad C, Sandvik L, Holmoy T, Harbo HF, Celius EG. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol 2008;255:49-55.
2. Mero IL. Studies of genetic risk factors in multiple sclerosis. Doctoral thesis: Faculty of Medicine, University of Oslo, 2012. ISBN 978-82-8264-473-0, no.1373.
3. Harbo HF, Lorentzen AR, Lie BA, Celius EG, Spurkland A. New gene map for multiple sclerosis. Tidsskr Nor Laegeforen 2011;131:2126-30.
4. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012;248:87-103.
5. Simpson S Jr, Blizzard L, Otahal P, Van Der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:1132-41.
6. Ramagopalan SV, Sadovnick AD. Epidemiology of multiple sclerosis. Neurol Clin 2011;29:207-17.
7. Harbo HF, Utsi E, Lorentzen AR et al. Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens 2007;69:299-304.
8. Celius EG, Smestad C. Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades. Acta Neurol Scand Suppl 2009;189:27-9.
9. Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010;5:271-7.
10. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
11. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009;73:696-701.
12. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32.
13. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150-1.
14. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
15. Hansen T, Skytthe A, Stenager E, Petersen HC, Bronnum-Hansen H, Kyvik KO. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005;11:504-10.
16. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972;1:1240-1.
17. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991;38:1-15.
18. Oksenberg JR, Barcellos LF, Cree BA et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74:160-7.
19. Barcellos LF, Oksenberg JR, Begovich AB et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-6.
20. The International Multiple Sclerosis Genetics Consortium (IMSGC), Wellcome Trust Case Control Consortium 2 (WTCCC2). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-9.
21. Barcellos LF, Sawcer S, Ramsay PP et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006;15:2813-24.
22. Link J, Lorentzen AR, Kockum I et al. Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol 2010;226:172-6.
23. Marrosu MG, Murru R, Murru MR et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 2001;10:2907-2916.
24. Brassat D, Salemi G, Barcellos LF et al. The HLA locus and multiple sclerosis in Sicily. Neurology 2005;64:361-3.
25. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Ornek I, Vaughan R, Eraksoy M. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol 1997;55:59-65.
26. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48:211-9.
27. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000;178:132-5.
28. Field J, Browning SR, Johnson LJ et al. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. PLoS One 2010;5:e13454.
29. Caillier SJ, Briggs F, Cree BA et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008;181:5473-80.
30. Harbo HF, Lie BA, Sawcer S et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004;63:237-47.
31. Lorentzen AR, Karlsen TH, Olsson M et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 2009;65:658-66.
32. Link J, Kockum I, Lorentzen AR et al. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS ONE 2012;7:e36779.
33. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008;131:3118-31.
34. Sawcer S, Ban M, Maranian M et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-67.
35. International Multiple Sclerosis Genetics Consortium (IMSGC). Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62.
36. Lundmark F, Duvefelt K, Iacobaeus E et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007;39:1108-13.
37. Gregory SG, Schmidt S, Seth P et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39:1083-91.
38. Kemppinen A, Sawcer S, Compston A. Genome-wide association studies in multiple sclerosis: lessons and future prospects. Brief Funct Genomics 2011;10:61-70.
39. The International Multiple Sclerosis Consortium (IMSGC). The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 2009;10:11-4.
40. Ban M, Goris A, Lorentzen AR et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 2009;17:1309-1313.
41. Mero IL, Lorentzen AR, Ban M et al. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet 2010;18:502-4.
42. Patsopoulos NA, Esposito F, Reischl J et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
43. Barcellos LF, Kamdar BB, Ramsay PP et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006;5:924-31.
44. Patsopoulos NA, De Bakker PI, Esposito F et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
45. Sirota M, Schaub MA, Batzoglou S, Robinson WH, Butte AJ. Autoimmune disease classification by inverse association with SNP alleles. PLoS Genet 2009;5:e1000792.
46. Undlien DE, Kockum I, Ronningen KS et al. HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes. Tissue Antigens 1999;54:543-51.
47. Visscher PM, Brown MA, Mccarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012;90:7-24.
48. Baranzini SE, Nickles D. Genetics of multiple sclerosis: swimming in an ocean of data. Curr Opin Neurol 2012;25:239-45.
49. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-64.
50. Mero IL, Ban M, Lorentzen AR et al. Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. Genes Immun 2011;12:191-8.
51. Zuvich RL, Bush WS, Mccauley JL et al. Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. Hum Mol Genet 2011;20:3517-24.
52. Davison LJ, Wallace C, Cooper JD et al. Long-range DNA looping and gene expression analyses identify DEXI as an autoimmune disease candidate gene. Hum Mol Genet 2012;21:322-33.
53. De Jager PL, Baecher-Allan C, Maier LM et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA 2009;106:5264-9.
54. Comabella M, Vandenbroeck K. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. Curr Neurol Neurosci Rep 2011;11:484-91.
55. Annunziata P, Giorgio A, De Santi L et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci 2006;244:97-102.
56. Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Mult Scler 2010;16:796-800.
57. Vandenbroeck K, Comabella M. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J Interferon Cytokine Res 2010;30:727-32.
58. Gross R, Healy BC, Cepok S et al. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2011;233:168-74.
59. Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9:381-90.
60. Hemminki K, Forsti A, Houlston R, Bermejo JL. Searching for the missing heritability of complex diseases. Hum Mutat 2011;32:259-62.
61. Hedstrom AK, Sundqvist E, Baarnhielm M et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011;134:653-64.
62. Ramagopalan SV, Dyment DA, Cader MZ et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70:881-6.
63. Gregory A, Dendrou CA, Attfield KE et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012;488(7412):508-11.